Decentralized Trials That Scale Globally Without Compliance Risks - with Emma Vitalini of Amgen

Clinical trial enrollment remains a bottleneck, with up to 80 % of studies missing recruitment targets. Emma Vitalini explains how AI can sift through unstructured electronic health records and genomic reports, turning raw data into actionable patient cohorts in minutes rather than weeks. The falling cost of sequencing and proteomics allows sponsors to match molecular mechanisms to individual patients, boosting diversity by reaching underserved populations. By automating the screening process, AI shortens the time from identification to enrollment, helping companies bring therapies to market faster while preserving scientific rigor.

Decentralized trial platforms translate those AI insights into compliant, patient‑centric workflows. Modular e‑consent tools let participants read, ask questions, and sign digitally, while AI‑driven chat assistants clarify jargon in real time. Wearables such as Apple Watch or FDA‑cleared biosensors continuously capture vitals, sleep patterns, and even voice cues, feeding objective outcomes back to the study without site visits. Because data residency rules differ across GDPR‑covered Europe, the United States, and emerging markets, plug‑and‑play APIs enable sponsors to query patient attributes without moving raw datasets, preserving privacy and reducing cross‑border transfer costs.

Adopting AI‑powered decentralization also demands new leadership mindsets. Executives must prioritize patient empowerment, ensuring transparent consent and 24/7 digital support while keeping a human‑in‑the‑loop for safety escalations. When choosing technology, sponsors weigh vendor solutions against in‑house builds, evaluating proof‑of‑concept results, bias monitoring, and model agnosticism. A hybrid approach—leveraging proven platforms for scalability while retaining core algorithms internally—offers the best balance of speed, regulatory trust, and control over hallucinations. As the ecosystem matures, these strategies promise faster, more inclusive trials that deliver therapies to global populations with reduced compliance risk.